Qualitative and quantitative evaluation of the role of CBCT in rectal cancer radiotherapy.

Radiol Med

Faculty of Informatics & Science, University of Oradea, 410087, Oradea, Romania.

Published: November 2024

Verifying patients' position and internal anatomical changes are important steps in the radiotherapy of rectal cancer. Cone Beam Computed Tomography (CBCT) is an advanced imaging method that allows for the quantification of these modifications, ensuring the delivery of radiation dose to the tumor volume, while protecting surrounding organs at risk. The aim of this review is to discuss and analyze the benefits offered by this method of imaging on board the linear accelerator. In view of this, a systematic search of the scientific literature in the Medline/PubMed database was performed for publications over the last decade, with 20 articles found to be relevant for this study. To highlight the benefits of this imaging technique in rectal cancer, the frequency of CBCT use, identification of tumor volume and organs at risk on CBCT images, quantification of the movement of these organs and tumor volume, analysis of positioning errors as well as evaluation of dosimetric parameters were analyzed.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11547-024-01932-6DOI Listing

Publication Analysis

Top Keywords

rectal cancer
12
tumor volume
12
organs risk
8
qualitative quantitative
4
quantitative evaluation
4
evaluation role
4
cbct
4
role cbct
4
cbct rectal
4
cancer radiotherapy
4

Similar Publications

Background: Lymphadenectomy for rectal cancer is clearly defined by total mesorectal excision (TME). The analogous surgical strategy for the colon, the complete mesocolic excision (CME), follows the same principles of dissection in embryologically predefined planes.

Method: This narrative review initially identified key issues related to lymphadenectomy of rectal and colon cancer.

View Article and Find Full Text PDF

The purpose of this study was to identify whether the preoperative hemoglobin to albumin ratio (HAR) could predict the prognosis of patients who underwent colorectal cancer (CRC) radical resection. This study enrolled 4018 consecutive CRC patients, calculating HAR as the hemoglobin count divided by albumin count. Patients were divided into the high and low HAR groups based on a cut-off value (0.

View Article and Find Full Text PDF

Prostate cancer (PCa) has high prevalence rates in men and is a leading cause of cancer-related death. Transrectal (TR) biopsy has traditionally been the gold standard for diagnosis, but transperineal (TP) biopsy is increasingly favoured due to its lower infection risk. However, debate remains regarding which method has superior cancer detection rates.

View Article and Find Full Text PDF

Objectives: The objective is to evaluate the efficacy of F-fluorodeoxyglucose positron emission tomography (F-FDG-PET) computed tomography (CT) in the evaluation of tumor response to preoperative/palliative chemoradiotherapy (CRT) for advanced colorectal cancer; including metastatic cancer at primary presentation and recurrent cancers with local and/or distant metastasis.

Materials And Methods: Fifty patients with advanced rectal cancer underwent two point imaging with 18 FDG PET-CT before and after 3 weeks of completion of preoperative/palliative CRT in between 2016 and 2022. Patients with locally recurrent cancer also underwent radical surgery.

View Article and Find Full Text PDF

An increasing number of autosomal recessive forms of adenomatous polyposis have been described, but some in very few cases. Here, we describe a rare case of biallelic germline pathogenic variants in the MLH3 gene, implicating it as a potential cause of early colorectal cancer. The patient, a 47-year-old woman, presented with rectal bleeding, leading to the discovery of a malignant rectal tumor and adenomas during colonoscopy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!